Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming
Advanced Science · 2024-12 · 11 (48)
DOI: 10.1002/advs.202409499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 28.10.2024. Verfasst von Han She und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Myocardial Reperfusion Injury, Disease Models, Animal. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Medical Young Talents Program.
Abstract (Originalsprache)
Myocardial ischemia‐reperfusion injury (MIRI) significantly worsens the outcomes of patients with cardiovascular diseases. Dexmedetomidine (Dex) is recognized for its cardioprotective properties, but the related mechanisms, especially regarding metabolic reprogramming, have not been fully clarified. A total of 60 patients with heart valve disease are randomly assigned to Dex or control group. Blood samples are collected to analyze cardiac injury biomarkers and metabolomics. In vivo and vitro rat models of MIRI are utilized to assess the effects of Dex on cardiac function, lactate production, and mitochondrial function. It is found that postoperative CK‐MB and cTNT levels are significantly lower in the Dex group. Metabolomics reveals that Dex regulates metabolic reprogramming and reduces lactate level. In Dex‐treated rats, the myocardial infarction area is reduced, and myocardial contractility is improved. Dex inhibits glycolysis, reduces lactate, and improves mitochondrial function following MIRI. Lactylation proteomics identifies that Dex reduces the lactylation of Malate Dehydrogenase 2(MDH2), thus alleviating myocardial injury. Further studies reveal that MDH2 lactylation induces ferroptosis, leading to MIRI by impairing mitochondrial function. Mechanistic analyses reveal that Dex upregulates Nuclear Receptor Subfamily 3 Group C Member 1(NR3C1) phosphorylation, downregulates Pyruvate Dehydrogenase Kinase 4 (PDK4), and reduces lactate production and MDH2 lactylation. These findings provide new therapeutic targets and mechanisms for the treatment for MIRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- Shock and Transfusion Department, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- Department of Urology Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing University of Chinese Medicine, Chongqing Traditional Chinese Medicine Hospital, Chongqing, 400021, China.
- Department of Research and Development, Chongqing Precision Medical Industry Technology Research Institute, Chongqing, 400000, China.
ORCID-Profile: Tao Li
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Medical Young Talents Program
- High-Level Military Technological Innovation Talent Program
- Chongqing Talent Program: Innovative Leading Talents
- Chongqing Natural Science Foundation Innovation and Development Joint Fund (Chongqing Education Commission)
- Sprint Program of Joint Medical Research of Chongqing Science and Chongqing Health Commission
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
She, H., Hu, Y., Zhao, G., Du, Y., Wu, Y., Chen, W., Li, Y., Wang, Y., Tan, L., Zhou, Y., Zheng, J., Li, Q., Yan, H., Mao, Q., Zuo, D., Liu, L., & Li, T. (2024). Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming. Advanced Science, 11(48). https://doi.org/10.1002/advs.202409499
Vancouver
She H, Hu Y, Zhao G, Du Y, Wu Y, Chen W, et al. Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming. Advanced Science. 2024;11(48). doi:10.1002/advs.202409499
BibTeX
@article{She2024,
author = {She, Han and Hu, Yi and Zhao, Guozhi and Du, Yunxia and Wu, Yinyu and Chen, Wei and Li, Yong and Wang, Yi and Tan, Lei and Zhou, Yuanqun and Zheng, Jie and Li, Qinghui and Yan, Hong and Mao, Qingxiang and Zuo, Deyu and Liu, Liangming and Li, Tao},
title = {Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {48},
doi = {10.1002/advs.202409499}
}
EUVIMED